Premium
Systematic review with meta‐analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre‐existing inflammatory bowel diseases
Author(s) -
Meserve Joseph,
Facciorusso Antonio,
Holmer Ariela K.,
Annese Vito,
Sandborn William J.,
Singh Siddharth
Publication year - 2021
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16217
Subject(s) - medicine , inflammatory bowel disease , adverse effect , discontinuation , immune system , immunology , oncology , disease
Observational studies suggest that patients with autoimmune diseases may be at higher risk of immune related adverse events with immune checkpoint inhibitor therapy. 40% experience relapse of pre‐existing IBD, of whom 76% require corticosteroids and 37% require biologics to control disease.